{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:43:56Z","timestamp":1740149036354,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12325-024-02790-4","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T20:01:41Z","timestamp":1709668901000},"page":"1711-1727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"41","author":[{"given":"Daniel J.","family":"Simmons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren S.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus J.","family":"Healey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoxin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesica M.","family":"Levingston Mac Leod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janvi","family":"Sah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"2790_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2790_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:6.","journal-title":"Nat Rev Dis Prim"},{"key":"2790_CR3","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"J-W Park","year":"2015","unstructured":"Park J-W, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155\u201366.","journal-title":"Liver Int"},{"key":"2790_CR4","unstructured":"NIH National Cancer Institute. Surveillance Epidemiology and End Results Program. SEER*Stat Software. www.seer.cancer.gov\/seerstat. Accessed Feb 12, 2021."},{"key":"2790_CR5","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1200\/JCO.2015.64.7412","volume":"34","author":"JL Petrick","year":"2016","unstructured":"Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol. 2016;34:1787\u201394.","journal-title":"J Clin Oncol"},{"key":"2790_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Hepatocellular Carcinoma. Version 1.2023. 2023. www.nccn.org\/guidelines. Accessed Mar 10, 2023."},{"key":"2790_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"2790_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100702","volume":"5","author":"CAM Fulgenzi","year":"2023","unstructured":"Fulgenzi CAM, Scheiner B, Korolewicz J, et al. Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase\u00a0III trials. JHEP Rep. 2023;5:100702.","journal-title":"JHEP Rep"},{"key":"2790_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"2790_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase\u00a03 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"2790_CR11","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"A-L Cheng","year":"2022","unstructured":"Cheng A-L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862\u201373.","journal-title":"J Hepatol"},{"key":"2790_CR12","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.2147\/DDDT.S386829","volume":"16","author":"B Chen","year":"2022","unstructured":"Chen B, Zhang L, Cheng J, et al. Risk factors for hepatic encephalopathy in hepatocellular carcinoma after sorafenib or lenvatinib treatment: a real-world study. Drug Des Devel Ther. 2022;16:4429\u201337.","journal-title":"Drug Des Devel Ther"},{"key":"2790_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11136-021-02903-4","volume":"31","author":"N Patel","year":"2021","unstructured":"Patel N, Maher J, Lie X, et al. Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study. Qual Life Res. 2021;31:473\u201385.","journal-title":"Qual Life Res"},{"key":"2790_CR14","doi-asserted-by":"publisher","first-page":"HEP27","DOI":"10.2217\/hep-2020-0024","volume":"7","author":"A Aly","year":"2020","unstructured":"Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepat Oncol. 2020;7:HEP27.","journal-title":"Hepat Oncol"},{"key":"2790_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","volume":"22","author":"PR Galle","year":"2021","unstructured":"Galle PR, Finn RS, Qin S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase\u00a03 trial. Lancet Oncol. 2021;22:991\u20131001.","journal-title":"Lancet Oncol"},{"key":"2790_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1504","volume":"5","author":"LS Lal","year":"2022","unstructured":"Lal LS, Aly A, Le LB, Peckous S, Seal B, Teitelbaum A. Healthcare costs related to adverse events in hepatocellular carcinoma treatment: a retrospective observational claims study. Cancer Rep (Hoboken). 2022;5:e1504.","journal-title":"Cancer Rep (Hoboken)"},{"key":"2790_CR17","first-page":"296","volume":"5","author":"S Gandhi","year":"2014","unstructured":"Gandhi S, Khubchandani S, Iyer R. Quality of life and hepatocellular carcinoma. J Gastrointest Oncol. 2014;5:296\u2013317.","journal-title":"J Gastrointest Oncol"},{"key":"2790_CR18","unstructured":"Optum\u00ae. Clinformatics\u00ae Data Mart. 2017. https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/Clinformatics_for_Data_Mart.pdf. Accessed Aug 30, 2023."},{"key":"2790_CR19","unstructured":"US Food and Drug Administration. Tecentriq (atezolizumab): highlights of prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761034s025lbl.pdf. Accessed Jun 13, 2023."},{"key":"2790_CR20","unstructured":"US Food and Drug Administration. Lenvima (lenvatinib): highlights of prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206947s007lbl.pdf. Accessed Jun 13, 2023."},{"key":"2790_CR21","unstructured":"US Food and Drug Administration. Nexavar (sorafenib): highlights of prescribing information. 2005. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021923s020lbl.pdf. Accessed Jun 13, 2023."},{"key":"2790_CR22","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib. 2017. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-nivolumab-hcc-previously-treated-sorafenib. Accessed Jun 13, 2023."},{"key":"2790_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12029-019-00230-z","volume":"51","author":"MM Bonafede","year":"2020","unstructured":"Bonafede MM, Korytowsky B, Singh P, et al. Treatment patterns and economic burden by lines of therapy among patients with advanced hepatocellular carcinoma treated with systemic cancer therapy. J Gastrointest Cancer. 2020;51:217\u201326.","journal-title":"J Gastrointest Cancer"},{"key":"2790_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s12032-012-0345-2","volume":"30","author":"PR Brunocilla","year":"2013","unstructured":"Brunocilla PR, Brunello F, Carucci P, et al. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol. 2013;30:345.","journal-title":"Med Oncol"},{"key":"2790_CR25","doi-asserted-by":"publisher","first-page":"e1205","DOI":"10.1002\/onco.13812","volume":"26","author":"S George","year":"2021","unstructured":"George S, Bell EJ, Zheng Y, et al. The impact of adverse events on health care resource utilization, costs, and mortality among patients treated with immune checkpoint inhibitors. Oncologist. 2021;26:e1205\u201315.","journal-title":"Oncologist"},{"key":"2790_CR26","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.jhep.2019.08.015","volume":"71","author":"F Tovoli","year":"2019","unstructured":"Tovoli F, Ielasi L, Casadei-Gardini A, et al. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol. 2019;71:1175\u201383.","journal-title":"J Hepatol"},{"key":"2790_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109244","volume":"112","author":"J Zheng","year":"2022","unstructured":"Zheng J, Shao M, Yang W, Ren J, Chen X, Yang H. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: a systematic review and meta-analysis. Int Immunopharmacol. 2022;112:109244.","journal-title":"Int Immunopharmacol"},{"key":"2790_CR28","unstructured":"US Food and Drug Administration. Imjudo (tremelimumab-actl): highlights of prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761289lbl.pdf. Accessed Aug 15, 2023."},{"key":"2790_CR29","unstructured":"US Food and Drug Administration. Imfinzi (durvalumab): highlights of prescribing information. 2023. https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/9496217c-08b3-432b-ab4f-538d795820bd\/9496217c-08b3-432b-ab4f-538d795820bd_viewable_rendition__v.pdf. Accessed Aug 15, 2023."},{"issue":"suppl 1","key":"2790_CR30","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1016\/j.annonc.2023.04.487","volume":"34","author":"B Sangro","year":"2023","unstructured":"Sangro B, Chan S, Kelley RK, et al. SO-15 Four-year overall survival update from the phase\u00a03 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2023;34(suppl 1):S168.","journal-title":"Ann Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02790-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02790-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02790-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T09:36:35Z","timestamp":1711186595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02790-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2790"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02790-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"25 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Daniel J. Simmons: Employee and shareholder of AstraZeneca. Stephen J. Valerio: Employee and shareholder of AstraZeneca. Darren S. Thomas: Employee and shareholder of AstraZeneca. Marcus J. Healey: Former full-time employee of AstraZeneca at time of study. Current full-time employee of PharmaPRMAx, LLC. Zhuoxin Jiang: Former full-time employee of AstraZeneca at time of study. Current full-time employee of Daiichi Sankyo, Inc. Jesica M. Levingston Mac Leod: Employee of AstraZeneca. Yian Lin: Former full-time employee and shareholder of AstraZeneca at time of study. Current full-time employee of Novartis Pharmaceuticals Corporation. Janvi Sah: Employee and shareholder of AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This was a retrospective study using anonymous data; therefore, ethics committee approval was not required. However, the data were certified as de-identified by an independent statistical expert following the statistical de-identification rules of the Health Insurance Portability and Accountability Act (HIPAA) and managed according to customer data use agreements. Study authors received permission to use the Optum<sup>\u00ae<\/sup> Clinformatics<sup>\u00ae<\/sup> Data Mart claims database from Optum<sup>\u00ae<\/sup>.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}